Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: A quite rare phenomenon indeed

Cardiovascular Therapeutics

Volumn 28, Issue 3, 2010, Pages 153-160

  Mombelli, Giuliana ^a   Pazzucconi, Franco ^a   Bondioli, Alighiero ^a   Zanaboni, Annamaria ^b   Gaito, Sabrina ^b   Calabresi, Laura ^a,b   Sirtori, Cesare R ^a,b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Fenofibrate; High density lipoproteins (HDLs); Paradoxical decrease

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTILIPEMIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GENE CLUSTER; HEALTH SURVEY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; TREATMENT DURATION; AGED; BLOOD; DOWN REGULATION; DRUG COMBINATION; DYSLIPIDEMIAS; HEALTH CARE SURVEY; ITALY; MIDDLE AGED; REGISTER; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; DOWN-REGULATION; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MIDDLE AGED; PROCETOFEN; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME; FENOFIBRATE; HYPOLIPIDEMIC AGENTS;

EID: 77952199921     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00121.x     Document Type: Article

References (24)

1. Fruchart JC, Brewer HB Jr., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 1998 81 : 912 917.
2. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: Mechanisms of action and rational prescribing. Vasc Health Risk Manag 2008 4 : 991 1000.
3. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986 256 : 2835 2838.
4. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: Raising high-density lipoprotein cholesterol levels. Heart 2008 94 : 706 714.
5. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998 98 : 2088 2093.
6. Clavey V, Copin C, Mariotte MC, et al. Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem 1999 9 : 139 149.
7. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005 366 : 1849 1861.
8. Mombelli G, Banfi F, Falcioni S, Sirtori CR. Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer. Int J Cardiol 2009 133 : 412 414.
9. Sirtori CR, Montanari G, Gianfranceschi G, Sirtori M, Galli G, Bosisio E. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients. Eur J Clin Pharmacol 1985 28 : 619 624.
10. Glaysher JVHC. Paradoxical decreased in high density lipoprotein- cholesterol associated with statin and fenofibrate combination therapy. Br J Diab Vasc Dis 2007 24 : 295 297.
11. Magee G, Sharpe PC. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: A quite common phenomenon. J Clin Pathol 2009 62 : 250 253.
12. Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 2007 195 : 385 391.
13. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996 15 : 5336 5348.
14. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995 95 : 705 712.
15. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996 16 : 763 772.
16. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991 11 : 174 182.
17. Syvanne M, Nieminen MS, Frick MH, et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998 98 : 1993 1999.
18. Castellani LW, Nguyen CN, Charugundla S, et al. Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance. J Biol Chem 2008 283 : 11633 11644.
19. van 't Hooft FM, Ruotolo G, Boquist S, de Faire U, Eggertsen G, Hamsten A. Human evidence that the apolipoprotein a-II gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins. Circulation 2001 104 : 1223 1228.
20. Ribas V, Palomer X, Roglans N, et al. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. Biochim Biophys Acta 2005 1737 : 130 137.
21. Albers JJ, Warnick GR, Chenng MC. Quantitation of high density lipoproteins. Lipids 1978 13 : 926 932.
22. Liu Y, Ordovas JM, Gao G, et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: The genetics of lipid-lowering drugs and diet network study. Pharmacogenet Genom 2009 19 : 161 169.
23. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007 370 : 1687 1697.
24. Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomized controlled trial. Lancet 2009 373 : 1780 1788.